Distinct disease phases in muscles of facioscapulohumeral dystrophy patients identified by MR detected fat infiltration

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Janssen, Barbara H ^a   Voet, Nicoline B M ^a   Nabuurs, Christine I ^a   Kan, Hermien E ^a,b   De Rooy, Jacky W J ^a   Geurts, Alexander C ^a   Padberg, George W ^a   Van Engelen, Baziel G M ^a   Heerschap, Arend ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; BIOLOGICAL MARKER; CREATINE PHOSPHATE; FAT; PHOSPHATE;

ADULT; AGE; AGED; ARTICLE; BODY FAT DISTRIBUTION; CLINICAL ARTICLE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; FEMALE; HUMAN; IMAGING; LEG EDEMA; MALE; METABOLITE; MUSCLE LENGTH; MUSCLE STRENGTH; MUSCULAR FAT FRACTION; MUSCULAR FAT INFILTRATION; MUSCULOSKELETAL SYSTEM PARAMETERS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PHOSPHORYLATION; QUANTITATIVE ANALYSIS; THREE DIMENSIONAL IMAGING; TURBO INVERSION RECOVERY MAGNITUDE IMAGE;

ADENOSINE TRIPHOSPHATE; ADIPOSE TISSUE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; EDEMA; ENERGY METABOLISM; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; LEG; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, FACIOSCAPULOHUMERAL; PHOSPHATES; PROGNOSIS; YOUNG ADULT;

EID: 84897972387     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085416     Document Type: Article

References (45)

1. Padberg GW (1982) Facioscapulohumeral Disease. Leiden, The Netherlands: University of Leiden Thesis.
2. Lemmers RJ, van d, Klooster R, Sacconi S, Camano P, et al. (2010) A unifying genetic model for facioscapulohumeral muscular dystrophy. Science 329: 1650-1653.
3. van der Maarel SM, Tawil R, Tapscott SJ (2011) Facioscapulohumeral muscular dystrophy and DUX4: breaking the silence. Trends Mol Med 17: 252-258.
4. Pandya S, King WM, Tawil R (2008) Facioscapulohumeral dystrophy. Phys Ther 88: 105-113.
5. Tawil R (2008) Facioscapulohumeral muscular dystrophy. Neurotherapeutics 5: 601-606.
6. Gaeta M, Messina S, Mileto A, Vita GL, Ascenti G, et al. (2012) Muscle fatfraction and mapping in Duchenne muscular dystrophy: evaluation of disease distribution and correlation with clinical assessments. Preliminary experience. Skeletal Radiol 41: 955-961.
7. Wren TA, Bluml S, Tseng-Ong L, Gilsanz V (2008) Three-point technique of fat quantification of muscle tissue as a marker of disease progression in Duchenne muscular dystrophy: preliminary study. AJR Am J Roentgenol 190: W8-12.
8. Kan HE, Scheenen TWJ, Wohlgemuth M, Klomp DWJ, van Loosbroek-Wagenmans I, et al. (2009) Quantitative MR imaging of individual muscle involvement in facioscapulohumeral muscular dystrophy. Neuromuscul Disord 19: 357-362.
9. Heerschap A, den Hollander JA, Reynen H, Goris RJ (1993) Metabolic changes in reflex sympathetic dystrophy: a 31P NMR spectroscopy study. Muscle Nerve 16: 367-373. (Pubitemid 23094100)
10. Banerjee B, Sharma U, Balasubramanian K, Kalaivani M, Kalra V, et al. (2010) Effect of creatine monohydrate in improving cellular energetics and muscle strength in ambulatory Duchenne muscular dystrophy patients: a randomized, placebo-controlled 31P MRS study. Magn Reson Med 28: 698-707.
11. Barbiroli B, Funicello R, Iotti S, Montagna P, Ferlini A, et al. (1992) 31P-NMR spectroscopy of skeletal muscle in Becker dystrophy and DMD/BMD carriers. Altered rate of phosphate transport. J Neurol Sci 109: 188-195.
12. Barnes PR, Kemp GJ, Taylor DJ, Radda GK (1997) Skeletal muscle metabolism in myotonic dystrophy A 31P magnetic resonance spectroscopy study. Brain 120 (Pt 10): 1699-1711. (Pubitemid 27443047)
13. Grehl T, Müller K, Vorgerd M, Tegenthoff M, Malin JP, et al. (1998) Impaired aerobic glycolysis in muscle phosphofructokinase deficiency results in biphasic post-exercise phosphocreatine recovery in 31P magnetic resonance spectroscopy. Neuromuscul Disord 8: 480-488. (Pubitemid 28484821)
14. Lodi R, Muntoni F, Taylor J, Kumar S, Sewry CA, et al. (1997) Correlative MR imaging and 31P-MR spectroscopy study in sarcoglycan deficient limb girdle muscular dystrophy. Neuromuscul Disord 7: 505-511. (Pubitemid 28008959)
15. Trenell MI, Thompson CH, Sue CM (2006) Exercise and myotonic dystrophy: a 31P magnetic resonance spectroscopy and magnetic resonance imaging case study. Ann Neurol 59: 871-872. (Pubitemid 43673168)
16. Kan HE, Klomp DWJ, Wohlgemuth M, van Loosbroek-Wagemans I, van Engelen BGM, et al. (2010) Only fat infiltrated muscles in resting lower leg of FSHD patients show disturbed energy metabolism. NMR Biomed 23: 563-568.
17. Statland JM, Tawil R (2011) Facioscapulohumeral muscular dystrophy: molecular pathological advances and future directions. Curr Opin Neurol 24: 423-428.
18. Voet NBM, Bleijenberg G, Padberg GW, van Engelen BGM, Geurts ACH (2010) Effect of aerobic exercise training and cognitive behavioural therapy on reduction of chronic fatigue in patients with facioscapulohumeral dystrophy: protocol of the FACTS-2-FSHD trial. BMC Neurol 10: 56-56.
19. Ricci E, Galluzzi G, Deidda G, Cacurri S, Colantoni L, et al. (1999) Progress in the molecular diagnosis of facioscapulohumeral muscular dystrophy and correlation between the number of KpnI repeats at the 4q35 locus and clinical phenotype. Ann Neurol 45: 751-757. (Pubitemid 29260752)
20. van der Kooi EL, Vogels OJM, van Asseldonk RJGP, Lindeman E, Hendriks JCM, et al. (2004) Strength training and albuterol in facioscapulohumeral muscular dystrophy. Neurology 63: 702-708. (Pubitemid 39100829)
21. Wattjes MP, Kley RA, Fischer D (2010) Neuromuscular imaging in inherited muscle diseases. Eur Radiol 20: 2447-2460.
22. Tasca G, Pescatori M, Monforte M, Mirabella M, Iannaccone E, et al. (2012) Different molecular signatures in magnetic resonance imaging-staged facioscapulohumeral muscular dystrophy muscles. PLoS One 7: e38779.
23. Frisullo G, Frusciante R, Nociti V, Tasca G, Renna R, et al. (2011) CD8(+) T cells in facioscapulohumeral muscular dystrophy patients with inflammatory features at muscle MRI. J Clin Immunol 31: 155-166.
24. Felmlee JP, Ehman RL (1987) Spatial presaturation: a method for suppressing flow artifacts and improving depiction of vascular anatomy in MR imaging. Radiology 164: 559-564. (Pubitemid 17097985)
25. Lamminen AE (1990) Magnetic resonance imaging of primary skeletal muscle diseases: patterns of distribution and severity of involvement. Br J Radiol 63: 946-950.
26. Kuk JL, Saunders TJ, Davidson LE, Ross R (2009) Age-related changes in total and regional fat distribution. Ageing Res Rev 8: 339-348.
27. Naressi A, Couturier C, Devos JM, Janssen M, Mangeat C, et al. (2001) Java-based graphical user interface for the MRUI quantitation package. MAGMA 12: 141-152. (Pubitemid 32510133)
28. Vanhamme L, van den Boogaart A, Van Huffel S (1997) Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. J Magn Reson 129: 35-43. (Pubitemid 127454051)
29. Taylor DJ, Bore PJ, Styles P, Gadian DG, Radda GK (1983) Bioenergetics of intact human muscle. A 31P nuclear magnetic resonance study. Mol Biol Med 1: 77-94. (Pubitemid 14143202)
30. Tawil R, Van Der Maarel SM (2006) Facioscapulohumeral muscular dystrophy. Muscle Nerve 34: 1-15.
31. Richards M, Coppee F, Thomas N, Belayew A, Upadhyaya M (2012) Facioscapulohumeral muscular dystrophy (FSHD): an enigma unravelled? Hum Genet 131: 325-340.
32. Sookhoo S, Mackinnon I, Bushby K, Chinnery PF, Birchall D (2007) MRI for the demonstration of subclinical muscle involvement in muscular dystrophy. Clin Radiol 62: 160-165. (Pubitemid 46024209)
33. Fischmann A, Hafner P, Fasler S, Gloor M, Bieri O, et al. (2012) Quantitative MRI can detect subclinical disease progression in muscular dystrophy. J Neurol 259: 1648-1654.
34. Gaeta M, Mileto A, Mazzeo A, Minutoli F, Di Leo R, et al. (2011) MRI findings, patterns of disease distribution, and muscle fat fraction calculation in five patients with Charcot-Marie-Tooth type 2 F disease. Skeletal Radiol 41: 515-524.
35. Snider L, Geng LN, Lemmers RJ, Kyba M, Ware CB, et al. (2010) Facioscapulohumeral dystrophy: incomplete suppression of a retrotransposed gene. PLoS Genet 6: e1001181.
36. Tassin A, Laoudj-Chenivesse D, Vanderplanck C, Barro M, Charron S, et al. (2013) DUX4 expression in FSHD muscle cells: how could such a rare protein cause a myopathy? J Cell Mol Med 17: 76-89.
37. McMahon CJ, Wu JS, Eisenberg RL (2010) Muscle edema. AJR Am J Roentgenol 194: W284-292.
38. May DA, Disler DG, Jones EA, Balkissoon AA, Manaster BJ (2000) Abnormal signal intensity in skeletal muscle at MR imaging: patterns, pearls, and pitfalls. Radiographics 20 Spec No: S295-315.
39. Friedman SD, Poliachik SL, Otto RK, Carter GT, Budech CB, et al. (2013) Longitudinal features of stir bright signal in FSHD. Muscle Nerve 31: 155-166.
40. Friedman SD, Poliachik SL, Carter GT, Budech CB, Bird TD, et al. (2012) The magnetic resonance imaging spectrum of facioscapulohumeral muscular dystrophy. Muscle Nerve 45: 500-506.
41. Kemp GJ, Taylor DJ, Dunn JF, Frostick SP, Radda GK (1993) Cellular energetics of dystrophic muscle. J Neurol Sci 116: 201-206. (Pubitemid 23176857)
42. Kushmerick MJ, Moerland TS, Wiseman RW (1992) Mammalian skeletal muscle fibers distinguished by contents of phosphocreatine, ATP, and Pi. Proc Natl Acad Sci U S A 89: 7521-7525.
43. Takahashi H, Kuno SY, Katsuta S, Shimojo H, Masuda K, et al. (1996) Relationships between fiber composition and NMR measurements in human skeletal muscle. NMR Biomed 9: 8-12. (Pubitemid 26310153)
44. Dubowitz V, Sewry CA (2007) Chapter 14: Muscular dystrophies and allied disorders V: facioscapulohumeral dystrophy, myotonic dystrophy, oculopharyngeal muscular dystrophy. Muscle biopsy : a practical approach United States: Elsevier Health Sciences.
45. Statland JM, McDermott MP, Heatwole C, Martens WB, Pandya S, et al. (2013) Reevaluating measures of disease progression in facioscapulohumeral muscular dystrophy. Neuromuscul Disord 23: 306-312.